MIR483

Summary

MIR483 (microRNA 483, HGNC:32340) is a microRNA gene on chromosome 11p15.5.

microRNAs (miRNAs) are short (20-24 nt) non-coding RNAs that are involved in post-transcriptional regulation of gene expression in multicellular organisms by affecting both the stability and translation of mRNAs. miRNAs are transcribed by RNA polymerase II as part of capped and polyadenylated primary transcripts (pri-miRNAs) that can be either protein-coding or non-coding. The primary transcript is cleaved by the Drosha ribonuclease III enzyme to produce an approximately 70-nt stem-loop precursor miRNA (pre-miRNA), which is further cleaved by the cytoplasmic Dicer ribonuclease to generate the mature miRNA and antisense miRNA star (miRNA*) products. The mature miRNA is incorporated into a RNA-induced silencing complex (RISC), which recognizes target mRNAs through imperfect base pairing with the miRNA and most commonly results in translational inhibition or destabilization of the target mRNA. The RefSeq represents the predicted microRNA stem-loop.

Source: NCBI Gene 619552 — RefSeq curated summary.

At a glance

• Gene type: non-coding (miRNA) — no protein product; not a drug target. Variant/disease associations are omitted (they would be positional, from an overlapping protein-coding gene).

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:32340
Approved symbol	MIR483
Name	microRNA 483
Location	11p15.5
Locus type	RNA, micro
Status	Approved
Aliases	hsa-mir-483
Ensembl gene	ENSG00000207805
Ensembl biotype	miRNA
Entrez	619552
RNAcentral	URS000018B0EE — miRNA, 76 nt, 6 organism(s)

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 miRNA

ENST00000385070

RefSeq mRNA: 0 — MANE Select: None

Canonical transcript exons

ENST00000385070 — 1 exons

Exon	Start	End
ENSE00001500076	2134134	2134209

Expression profiles

Bgee: expression breadth broad, 90 present calls, max score 98.15.

Top tissues by expression

114 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
adrenal tissue	UBERON:0018303	98.15	gold quality
placenta	UBERON:0001987	94.72	gold quality
apex of heart	UBERON:0002098	82.42	gold quality
monocyte	CL:0000576	78.97	gold quality
saliva-secreting gland	UBERON:0001044	78.72	gold quality
bone marrow	UBERON:0002371	77.28	silver quality
trachea	UBERON:0003126	76.98	gold quality
dorsal plus ventral thalamus	UBERON:0001897	76.49	gold quality
corpus callosum	UBERON:0002336	76.18	gold quality
dorsal root ganglion	UBERON:0000044	75.92	gold quality
muscle of leg	UBERON:0001383	75.87	gold quality
temporal lobe	UBERON:0001871	75.39	gold quality
endometrium	UBERON:0001295	74.83	gold quality
thymus	UBERON:0002370	74.72	gold quality
skeletal muscle tissue	UBERON:0001134	74.46	silver quality
amygdala	UBERON:0001876	74.31	gold quality
frontal pole	UBERON:0002795	74.13	gold quality
adrenal gland	UBERON:0002369	73.99	gold quality
stomach	UBERON:0000945	73.64	gold quality
paraflocculus	UBERON:0005351	73.52	gold quality
endocervix	UBERON:0000458	73.34	gold quality
gastrocnemius	UBERON:0001388	73.27	gold quality
middle frontal gyrus	UBERON:0002702	73.26	gold quality
liver	UBERON:0002107	73.19	gold quality
heart left ventricle	UBERON:0002084	73.04	gold quality
heart	UBERON:0000948	72.99	gold quality
body of pancreas	UBERON:0001150	72.50	gold quality
pancreas	UBERON:0001264	72.44	gold quality
right lobe of liver	UBERON:0001114	71.46	gold quality
vagina	UBERON:0000996	71.26	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.18

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 40)

• miR-483-3p has a role in cancer at the IGF2/483 locus (PMID:20388800)
• Findings identify miR-483-3p as a potent regulator of DPC4/Smad4, which may provide a novel therapeutic strategy for the treatment of DPC4/Smad4-driven pancreatic cancer. (PMID:21112326)
• This study showed the up-regulation of miR-483-3p in 2 distinct models of wound healing: scratch-injured cultures of human keratinocytes and wounded skin in mice. (PMID:21676945)
• Data show that serum response factor (SRF) is one of miR-483-5p target genes. (PMID:21893058)
• The miR-483- 3p represses the expression of GDF3 that is required for lipid accumulation at the late stages of differentiation. (PMID:22223106)
• miR-483-5p can serve as a tumor suppressor in gliomas (PMID:22465663)
• miR-483-5p, an intragenic microRNA of the imprinted IGF2, regulates MeCP2 levels through a human-specific binding site in the MECP2 long 3’ UTR (PMID:23431031)
• Serum miR-483-5p and miR-195 are predictive of recurrence risk in adrenocortical cancer patients. (PMID:23756429)
• miR-483-3p suppresses growth of squamous cell carcinomas due to its pro-apoptotic properties. (PMID:24067364)
• miR483-3p and Smad4 expression may help in distinguishing adrenal cortical carcinomas and adenomas. (PMID:24102952)
• MiR-34a and miR-483-5p are candidate serum biomarkers for distinguishing between benign and malignant adrenocortical tumors. (PMID:24238045)
• the IGF2 mRNA itself is transcriptionally up-regulated by miR-483-5p (PMID:24298054)
• the AT1R-regulated miR-483-3p as a potential negative regulator of steady-state levels of renin-angiotensin system components. (PMID:24976017)
• miR-483-5p has the potential to be a predictor of myeloma survival. (PMID:25216866)
• these findings suggest that measurement of the plasma miR483-3p level is useful for discriminating PDAC from IPMN, and that the plasma miR21 level predicts outcome of PDAC patients. (PMID:25384963)
• High serum MIR483 levels are associated with atopic dermatitis. (PMID:25531302)
• Colorectal cancer primarily metastasizes to the liver; by functionally screening 661 microRNAs (miRNAs) in parallel during liver colonization, study identified miR-551a and miR-483 as robust endogenous suppressors of liver colonization and metastasis. (PMID:25601461)
• Results show that miR-483-5p expression level is up-regulated in polycystic ovary syndrome patients and inversely correlated with notch3 and MAPk3 levels and that Notch3 and MAPK3 are the direct targets of MIR483. (PMID:25622783)
• microRNAs 221 and 483-5p respond to the loss of chondrocyte matrix interaction by respectively stimulating proliferation by suppression of inhibitors of cell division (PMID:25738598)
• Study revealed that a novel mitochondrial fission pathway composed of miR-483-5p and FIS1 regulates cisplatin sensitivity. (PMID:25843291)
• High serum miR483 is associated with pancreatic cancer-associated new-onset diabetes mellitus. (PMID:25991015)
• using an expression Quantitative Trait Loci (eQTL) analysis, regulatory SNPs for miRNA miR-483-3p that were also directly associated with PrCa were found. (PMID:26020509)
• These results suggest that aberrant miR-483-3p expression is an early event in pancreatic ductal adenocarcinoma tumorigenesis and is associated with tumor differentiation and prognosis (PMID:26124009)
• miR-483-5p has a role in oral squamous cell carcinoma (PMID:26224475)
• miR-483-5p may play an important role in reducing insulin resistance, and miR-486-5p may promote cumulus cell proliferation through activation of PI3K/Akt. New insights into the mechanisms involved in PCOS by pathways possibly regulated by miRNAs. (PMID:26283014)
• These results constitute a demonstration of the altered regulation of miR-34a and miR-483-3p in the livers of alcoholic hepatitis (PMID:26403328)
• MicroRNA-483-3p has an inhibitory effect on ECM production in HTMCs through downregulating Smad4, which indicates that miR-483-3p may serve as a potential therapeutic target in glaucoma. (PMID:26747772)
• Ectopic expression of miR-483-3p in esophageal squamous cell carcinoma cells could downregulate the protein level of etoposide induced 2.4 (EI24), which is a tumor suppressor and has not been reported in esophageal squamous cell carcinoma. (PMID:26801660)
• miR-483-3p is upregulated in Endothelial progenitor cells (EPCs) from deep vein thrombosis patients, and it targets SRF to decrease EPCs migration and tube formation. (PMID:26801758)
• miR-483-5p and miR-194 showed deregulated expression in cholangiocarcinoma compared with controls. (PMID:26864161)
• Data indicate that miR-145-5p and miR-483-3p expressions related to TP53 activity and mutational status. (PMID:27120784)
• IGF2 may exert its oncofunction, at least partly, through its parasitic miR-483 which suppressed DLC-1 in colorectal cancer (CRC) cells. Serum miR-483-5p has an acceptable sensitivity for the detection of CRC, making it a potential non-invasive biomarker for CRC screening (PMID:27366946)
• Overexpression of miR-483-5p induces gastric cancer stem cells invasion and self-renewal. (PMID:27511210)
• miR-483 is a self-regulating microRNA and can activate its own expression via USF1 (PMID:27693430)
• 6 microRNAs (miRNAs) hsa-mir-483-5p, hsa-mir-486-5p, hsa-30b-5p, hsa-mir-200a-3p, hsa-mir-502-3p and hsa-mir-142-3p are selected as most promising plasma biomarker candidates for the detection of early Alzheimer’s disease (AD). (PMID:28179587)
• Increased miR483 expression is associated with esophageal squamous cell carcinoma. (PMID:28211800)
• constitutive overexpression of miR-483 in bone marrow-derived mesenchymal stem cells inhibits chondrogenesis (PMID:28244607)
• These findings suggest that miR4835p may play an important and protective role in patients with COPD and may serve as a useful biomarker and for early detection of COPD as well as a potential therapeutic tool. (PMID:28534971)
• miR-483-5p mediated the downregulation of RBM5 expression that promotes cancer cell proliferation and invasion in prostate cancer. (PMID:28727371)
• miR-483-5p overexpression significantly decreased the levels of COL2A1 and aggrecan mRNAs, and increased those of RUNX2 and MMP13 mRNAs, by down-regulating TGF-beta1 expression. (PMID:28924102)

Cross-species orthologs

0 orthologs

Protein

Non-coding RNA — no protein product; not a drug target.

Function

No curated pathway, Gene-Ontology, or interaction data.

Disease & clinical

No curated disease, variant, or cancer-driver associations.

Drugs & pharmacology

No drug or pharmacology data — not an established drug target.